Incannex Healthcare Limited (NASDAQ: IXHL) completed a registered direct offering of 2 million shares of common stock at $5.00 per share and 2 million accompanying common warrants exercisable at $6.50 per share, with warrants expiring on March 13, 2031. The transaction is expected to generate approximately $10 million in gross proceeds, and if the warrants are exercised in full for cash, an additional $13 million could be raised, bringing the total potential gross proceeds to about $23 million.
The company will use the net proceeds to fund the DReAMzz Phase 2 crossover study for its lead sleep‑apnea candidate IHL‑42X and to support general corporate purposes. The study is designed to refine the drug’s efficacy and strengthen the clinical package ahead of a planned Phase 3 program in the second half of 2027.
Incannex’s move to a registered direct offering follows the termination of its at‑the‑market facility, which had previously raised roughly $108.4 million. The shift signals a strategic preference for a more structured equity raise that provides clearer funding visibility and reduces reliance on continuous equity sales.
Investors reacted negatively to the announcement, citing concerns over dilution from the new shares and warrants and the company’s ongoing need for capital to fund its clinical pipeline.
"Following the strong, statistically significant outcomes from our Phase 2 RePOSA trial, we believe IHL‑42X is emerging as one of the most promising oral therapies in development for obstructive sleep apnea. The optimization study we are initiating is designed to further refine the drug’s efficacy while strengthening the clinical package ahead of Phase 3. We believe the optimized study design provides a pathway that could accelerate development timelines, potentially shorten time to registration if successful, and allow us to progress efficiently through the end of Phase 3 development," said Joel Latham, President and Chief Executive Officer.
IHL‑42X is an oral fixed‑dose combination of dronabinol and acetazolamide that has received Fast Track designation from the FDA. The Phase 2 RePOSA trial demonstrated statistically significant improvements in key endpoints, including reductions in the Apnea‑Hypopnea Index, supporting the drug’s potential as a non‑invasive alternative to device‑based therapies.
Incannex has a history of operating losses and negative free cash flow, but the new capital infusion is intended to preserve cash for the upcoming Phase 3 program while supporting ongoing clinical development and corporate operations.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.